3D Prostate Mapping Biopsy Shows Staging Accuracy-- Eric Metcalf
Thursday, August 6, 2009
THURSDAY, Aug. 6 (HealthDay News) -- Three-dimensional prostate mapping biopsy (3D-PMB) may provide better accuracy in staging prostate cancer, which could have a major effect on patients' outcomes, according to research published online Aug. 3 in the Journal of Clinical Oncology.
Gary Onik, M.D., of Florida Hospital Celebration Health, and colleagues analyzed data from 180 patients who were earlier found to have unilateral prostate cancer with traditional transrectal ultrasound (TRUS) biopsy. Patients underwent transperineal 3D-PMB, with biopsies taken every 5 millimeters throughout the volume of the prostate. A median of 50 cores were taken per patient.
The researchers found that, of the patients whose TRUS biopsy found unilateral disease, 61.1 percent had bilateral disease on the 3D-PMB. In addition, 22.7 percent of patients were under-graded, with their Gleason scores increasing to seven or higher. The authors note that the results of the study indicate that TRUS biopsy provides an inaccurate assessment of extent and grade of disease.
"In conclusion, 3D-PMB is an extensive volume-based transperineal biopsy that can be safely used to more accurately stage prostate cancer patients. At the present time, when tailoring of patient treatment is increasingly being based on the extent and characteristics of a patient's cancer, 3D-PMB could have a profound effect on patient outcomes," Onlik and colleagues write.
Two co-authors reported financial relationships with Bostwick Laboratories.
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.